Fewer than a tenth of people who could benefit from obesity jabs like Wegovy can access them, caution the World Health Organization as it releases its first recommendations on the medications.
Given in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is urging more widespread and fairer availability to these injectable treatments.
Based on forecasts, in excess of 2,000,000,000 will be living with obesity by 2030 without intervention.
"The new guidance affirms that obesity is a long-term condition that can be managed with thorough and continuous support," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and supply-chain constraints are significant hurdles to universal access to the treatments that can help people shift substantial body mass, says the organization.
Skinny Jab Shortage
Despite the current most optimistic case, the manufacturing of these medications could only cover approximately 100 million people – under 10% of eligible patients, according to the WHO.
The guideline urges countries and companies to expand availability, via strategies including patent sharing.
A patent on the active ingredient – the core ingredient of the drug Wegovy – is due to expire in a number of countries in 2026.
The Way Obesity Jabs Function
GLP-1 drugs imitate a body's own hormone to delay gastric emptying, curb appetite and enhance satiety so individuals eat less.
Patients commonly begin shedding pounds in the initial weeks of beginning the once-weekly jabs.
Evidence suggests patients may regain a significant portion within a year of halting the medication, because their normal appetite resume.
To be above a healthy weight increases your chance for contracting medical conditions, including diabetes, cardiovascular issues, brain attack, and certain malignancies.
Obesity impacts people in every country and was linked to millions of fatalities worldwide in 2024, per the health agency.
